The Undeclared Ingredients Problem

The FDA's tainted supplements database lists hundreds of products marketed for sexual enhancement that contain undeclared pharmaceutical ingredients. Honey packs represent a significant and growing portion of this list. Between 2020 and 2025, the agency issued new warnings at a pace of roughly two to four products per month — and those are only the ones that were tested.

The actual number of adulterated products on the market is almost certainly higher. The FDA cannot test every product sold at every gas station, smoke shop, and convenience store in America. They test based on adverse event reports, consumer complaints, and targeted enforcement sweeps. Many tainted products are never flagged because no one reports a problem — or because the consumer does not connect their symptoms to the honey pack.

The economics are straightforward. A honey pack containing only honey, royal jelly, and herbal extracts may produce little to no noticeable effect on sexual performance. Adding a PDE5 inhibitor guarantees a physiological response — the product "works," the customer buys again, and word-of-mouth drives sales.

The active pharmaceutical ingredients are cheap to source in bulk from overseas chemical suppliers. A kilogram of sildenafil citrate powder can cost as little as a few hundred dollars on the gray market — enough to adulterate tens of thousands of packets. The profit margin on a product that costs pennies to make and sells for $5-15 per packet is enormous.

Manufacturers use several strategies to avoid regulatory action. Novel analogues — structurally similar but chemically distinct from known drugs — may not be detected by standard screening panels. By the time the FDA develops a test for a new analogue, manufacturers have moved on to the next one.

Frequent rebranding is another tactic. When a product receives an FDA warning, the same manufacturer may simply change the brand name, update the packaging, and continue selling an identical formulation. Without a centralized manufacturer registry, tracing these shell operations is difficult.

Decentralized distribution through gas stations, smoke shops, and small convenience stores makes enforcement impractical. The FDA can issue import alerts and seize shipments at the border, but products that are already in domestic circulation continue to sell until local stock runs out.

Under the Dietary Supplement Health and Education Act (DSHEA) of 1994, dietary supplements do not require FDA pre-market approval. Manufacturers are responsible for ensuring their products are safe and accurately labeled — but there is no mandatory pre-sale testing requirement. The FDA can only act after a product is already on the market and has been identified as adulterated or misbranded.

This reactive enforcement model means that for every product the FDA catches, others continue to sell undetected. The agency has called for legislative reform to give it mandatory recall authority for dietary supplements (currently, recalls are voluntary), but as of 2026, no such legislation has been enacted. Track the latest enforcement actions on our FDA timeline.

Until the regulatory framework changes, consumer vigilance is the primary defense. Check the FDA's tainted products list before purchasing any honey pack. Look for brands that proactively publish third-party lab results. Report adverse events to the FDA's MedWatch program — your report may trigger an investigation that protects others. And consider the fundamental question: if a product produces a dramatic pharmacological effect but claims to be "all natural," what is actually in it?